304 related articles for article (PubMed ID: 36290837)
1. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
[TBL] [Abstract][Full Text] [Related]
2. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
4. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
5. Current approach to Waldenström macroglobulinemia.
Kapoor P; Rajkumar SV
Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
[TBL] [Abstract][Full Text] [Related]
6. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
[TBL] [Abstract][Full Text] [Related]
7. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
[TBL] [Abstract][Full Text] [Related]
8. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
[TBL] [Abstract][Full Text] [Related]
9. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
11. Current approach to Waldenström Macroglobulinemia.
Ravi G; Kapoor P
Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
[TBL] [Abstract][Full Text] [Related]
12. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
13. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
14. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
15. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz R; Tedeschi A
Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
[TBL] [Abstract][Full Text] [Related]
16. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
Kapoor P; Paludo J; Abeykoon JP
Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
18. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
19. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Dimopoulos MA; Kastritis E; Owen RG; Kyle RA; Landgren O; Morra E; Leleu X; García-Sanz R; Munshi N; Anderson KC; Terpos E; Ghobrial IM; Morel P; Maloney D; Rummel M; Leblond V; Advani RH; Gertz MA; Kyriakou C; Thomas SK; Barlogie B; Gregory SA; Kimby E; Merlini G; Treon SP
Blood; 2014 Aug; 124(9):1404-11. PubMed ID: 25027391
[TBL] [Abstract][Full Text] [Related]
20. What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo JJ; Treon SP
Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
